Aditxt, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
ADTX$0.00-8.6%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year Ended · Year Ended | ||||
|---|---|---|---|---|
| December 31, 2025 · December 31, 2024 | ||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
| Net loss | $(42,787,043) | $(35,020,058) | ||
| Adjustments to reconcile net loss to net cash used in operating activities | ||||
| Stock-based compensation | 473,311 | 33,071 | ||
| Stock-based compensation from asset purchase | 10,000 | 6,712,663 | ||
| Depreciation expense | 269,271 | 613,918 | ||
| Amortization of intangible assets | 3,333 | 3,333 | ||
| Amortization of debt discount - note payable | 1,706,697 | 3,174,920 | ||
| Amortization of debt discount - note receivable | (220,689) | - | ||
| Loss on note exchange agreement | - | 208,670 | ||
| Modification of warrants for debt issuance costs | - | 376,901 | ||
| New principal from extension of notes, net of debt discount | - | 451,974 | ||
| Change in fair value of derivative liability | (14,515) | (414,501) | ||
| Change in fair value of Evofem warrants | (2,806,983) | - | ||
| Impairment of Evofem F-1 preferred stock | 23,766,209 | - | ||
| Disposal of fixed assets | - | 3,000 | ||
| Bargain purchase gain from purchase of Evofem convertible notes | (328,071) | - | ||
| Impairment of fixed assets | 412,005 | - | ||
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | 43,435 | 364,891 | ||
| Prepaid expenses | (613,983) | 214,011 | ||
| Deposits | 26,086 | 18,738 | ||
| Inventory | 5,471 | 734,257 | ||
| Accounts payable and accrued expenses | (5,632,893) | 5,095,091 | ||
| Settlement liability | - | 667,000 | ||
| Net cash used in operating activities | (25,688,359) | (16,762,121) | ||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||
| Purchase of fixed assets | (13,743) | - | ||
| Investment in convertible notes receivable and warrants | (2,425,000) | - | ||
| Investment in Evofem F-1 preferred stock | - | (5,000,000) | ||
| Net cash used in investing activities | (2,438,743) | (5,000,000) | ||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
| Proceeds from notes payable, related party | 678,000 | 467,000 | ||
| Proceeds from notes and convertible notes payable, net of offering costs | 1,191,018 | 4,149,153 | ||
| Repayments of note payable, related party | (793,000) | (727,000) | ||
| Repayments of note payable | (6,613,882) | (5,287,942) | ||
| Common stock, preferred stock, and warrants issued for cash, net of issuance costs | 44,128,225 | 21,166,343 | ||
| Cash from subscription receivable | 1,108,751 | 4,335,877 | ||
| Proceeds from exercises of warrants | - | 1,246,490 | ||
| Redemptions of A-1 preferred stock | (308,000) | - | ||
| Redemptions of C-1 preferred stock | (8,898,442) | (2,851,839) | ||
| Redemptions of D-1 preferred stock | - | (32) | ||
| Net cash provided by financing activities | 30,492,670 | 22,498,050 | ||
| NET INCREASE IN CASH | 2,365,568 | 735,929 | ||
| CASH AT BEGINNING OF PERIOD | 833,031 | 97,102 | ||
| CASH AT END OF PERIOD | $3,198,599 | $833,031 | ||
| Supplemental cash flow information: | ||||
| Cash paid for income taxes | $ | - | $ | - |
| Cash paid for interest | $2,465,546 | $1,235,640 | ||
| NONCASH INVESTING AND FINANCING ACTIVITIES: | ||||
| Issuance of shares for the conversion of notes payable | $ | - | $500,000 | |
| Debt discount from shares issued as inducement for note payable | $ | - | $1,576,431 | |
| Warrant modification | $ | - | $5,907,011 | |
| Issuance of shares in asset purchase | $ | - | $266,448 | |
| Shares issued for settlement | $ | - | $1,600,000 | |
| Return of notes payable from Evofem merger agreement | $ | - | $11,174,246 | |
| Accrued interest rolled into notes payable | $33,752 | $538,223 | ||
| Settlement of liability for Series C-1 Convertible Preferred Stock | $ | $667,000 | ||
| Subscription receivable | $ | - | $ | - |
| Exchange of warrants for Series C-1 convertible preferred stock | $ | - | $6,000,000 | |
| Derivative liability from conversion feature on preferred stock | $ | - | $429,018 | |
| ELOC payable | $328,071 | $ | - | |
| Series C-1 redemption payable | $237,498 | $1,354,774 | ||
| ELOC commitment fee stock payable | $2,250,000 | $2,250,000 | ||
| Loan in escrow | $2,000,000 | $ | - | |
| Reclassification of series A-1 preferred shares to liabilities | $517,444 | $ | - | |
| Write off of financed asset | $147,823 | $ | - | |
| Initial recognition of lease liability and right of use asset | $800,359 | $ | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.